Therapeutic Drug Monitoring
-
Adalimumab
Measuring Adalimumab drug concentrations in patients being treated with Adalimumab for chronic autoimmune and inflammatory conditions
-
Etanercept
Measuring Etanercept drug concentrations in patients being treated with Etanercept for chronic autoimmune conditions.
-
Free Anti-Adalimumab
Detecting the development of Anti-drug antibodies (ADAs) against Adalimumab in patients being treated with Adalimumab for chronic autoimmune and inflammatory conditions
-
Free Anti-Etanercept
Detecting the development of Anti-drug antibodies (ADAs) against Etanercept in patients being treated with Etanercept for chronic autoimmune conditions
-
Free Anti-Golimumab
Detecting the development of Anti-drug antibodies (ADAs) against Golimumab in patients being treated with Golimumab for chronic autoimmune and inflammatory conditions
-
Free Anti-Infliximab
Detecting the development of Anti-drug antibodies (ADAs) against Infliximab in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions
-
Free Anti-Rituximab
Detecting the development of Anti-drug antibodies (ADAs) against Rituximab in patients being treated with Rituximab
-
Free Anti-Trastuzumab
Detecting the development of Anti-drug antibodies (ADAs) against Trastuzumab in patients being treated with Trastuzumab
-
Free Anti-Ustekinumab
Detecting the development of Anti-drug antibodies (ADAs) against Ustekinumab in patients being treated with Ustekinumab for chronic autoimmune and inflammatory conditions
-
Free Anti-Vedolizumab
Detecting the development of Anti-drug antibodies (ADAs) against Vedolizumab in patients being treated with Vedolizumab for chronic autoimmune and inflammatory conditions
-
Golimumab
Measuring Golimumab drug concentrations in patients being treated with Golimumab for chronic autoimmune and inflammatory conditions
-
Infliximab
Measuring Infliximab drug concentrations in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions
-
Total Anti-Infliximab
Detecting the presence of total (free and bound) antibodies against Infliximab in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions.
-
Trastuzumab
Measuring Trastuzumab drug concentrations in patients being treated with Trastuzumab.
-
Ustekinumab
Measuring Ustekinumab drug concentrations in patients being treated with Ustekinumab for chronic autoimmune and inflammatory conditions
-
Vedolizumab
Measuring Vedolizumab drug concentrations in patients being treated with Vedolizumab for chronic autoimmune and inflammatory conditions
